References
- Bange J, Prechtl D, Cheburkin Y, et al. (2002). Cancer progression and tumor cell motility are associated with the FGFR4 Arg (388) allele. Cancer Res 62:840–7
- Choi KY, Rho YS, Kwon KH, et al. (2012). ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma. Cancer Biomark 12:115–24
- Dutra RL, de Carvalho MB, Dos Santos M, et al. (2012). FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One 7:e50747
- Ezzat S, Zheng L, Zhu XF, et al. (2002). Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109:69–78
- Frullanti E, Berking C, Harbeck N, et al. (2011). Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 20:340–7
- Giovannucci E, Fuchs CS, Ogino S. (2011). Relationship of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305:1685–94
- Jeffers M, LaRochelle WJ, Lichenstein HS. (2002). Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 6:469–82
- Kimman M, Norman R, Jan S, et al. (2011). The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev 13:411–20
- Ku G, Tan IB, Yau T, et al. (2012). Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol 13:e470–81
- Liu R, Li J, Xie K, et al. (2013). FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res 73:5926–35
- Peláez-García A, Barderas R, Torres S, et al. (2013). FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PLoS One 8:e63695
- Powers CJ, McLeskey SW, Wellstein A. (2000). Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–97
- Punt CJ, Tol J. (2009). More is less – combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 6:731–3
- Siena S, Sartore-Bianchi A, Nicolantonio F, et al. (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–24
- Spinola M, Leoni VP, Tanuma J, et al. (2005). FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 14:415–19